Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
Public ClinicalTrials.gov record NCT05156372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of a Randomized Chemo-periodized Adjuvant High-Intensity Interval Training Intervention to Improve Chemotherapy Tolerance in Men With Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to examine the use of high-intensity interval training (HIIT) and resistance training on docetaxel chemotherapy tolerability and toxicity in metastatic prostate cancer.
Study identification
- NCT ID
- NCT05156372
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2023
- Primary completion
- Nov 30, 2024
- Completion
- Nov 30, 2025
- Last update posted
- Feb 25, 2024
2023 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UT Health San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Prostate Cancer Metastatic trials
Other public records listing Prostate Cancer Metastatic. Sorted by last update posted; newest first. Not a recommendation.
- NCT05067140: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer Active, not recruiting
- NCT04030338: Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer Active, not recruiting
- NCT07593079: Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Not yet recruiting
- NCT04848337: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Active, not recruiting
- NCT06136624: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Recruiting
- NCT06171139: Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05156372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05156372 live on ClinicalTrials.gov.